News Conference News AHA 2021 Empagliflozin Retains Benefits in ‘True’ HFpEF Patients Todd Neale November 17, 2021
News Conference News AHA 2021 Empagliflozin Safe in Acute HF, Improves ‘Clinical Benefit’ Over Time: EMPULSE Shelley Wood November 14, 2021
News Conference News ESC 2021 EMPEROR-Preserved: Empagliflozin Improves Outcomes in HFpEF Todd Neale August 27, 2021
News Daily News Studies Explore Post-MI Use of Beta-blockers, Mineralocorticoid Receptor Antagonists Todd Neale July 09, 2021
News Conference News ACC 2021 Omecamtiv Mecarbil Has Biggest Benefit at Lowest EFs Todd Neale May 18, 2021
News Daily News Continue ACE Inhibitors/ARBs in COVID-19, New Study Confirms Michael O'Riordan April 02, 2021
News Daily News ACC’s HFrEF Update Includes ARNI, SGLT2 Inhibitor Trials Plus Tips for Care L.A. McKeown January 11, 2021